Urology News and Research

Latest Urology News and Research

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Predictive Biosciences today announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium, being held March 5-7 in San Francisco.

5 Mar 2010

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Men who undergo prostate-cancer screening should discuss with a doctor the uncertainties, risks and benefits of the test before it is performed, says Edward Partridge, M.D., president-elect of the American Cancer Society National Board of Directors and director of the University of Alabama at Birmingham Comprehensive Cancer Center.

5 Mar 2010

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Macroplastique effective for stress urinary incontinence in women

Uroplasty, Inc. highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the April 2010 print edition of The Journal of Urology(R). The 24-month study evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months. Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant improvement from their 12-month assessment. Additionally, 67% of the patients implanted with Macroplastique were dry at the 24-month follow-up visit.

4 Mar 2010

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy.

4 Mar 2010

Cystoscopy: Cost-effective method of detecting tumors

In a new study from The University of Texas M. D. Anderson Cancer Center, researchers found that cystoscopy, the standard for screening for recurrence of early-stage bladder cancer, is a cost-effective method of detecting tumors.

4 Mar 2010

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer.

4 Mar 2010

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED).

4 Mar 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. For the quarter CPEX reported revenues of $5.2 million and a net loss of $498,000. For the year CPEX reported revenues of $18.7 million and a net loss of $3.0 million.

3 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Robotic surgical technology with its three-dimensional, high-definition view gives surgeons the sensation of touch, even as they operate from a remote console. A new study describes the phenomenon, called intersensory integration, and reports that surgical outcomes for prostate cancer surgery using minimally invasive robotic technology compare favorably with traditional invasive surgery.

3 Mar 2010

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.

3 Mar 2010

My Little Miracle Essay Contest: Winners to receive education fund prizes to support their children's future

If you are a parent who has conceived using Ferring Pharmaceuticals' fertility products, you can win a $10,000 education fund to support your child's future. Two other education fund prizes will also be awarded.

2 Mar 2010

Watson Pharmaceuticals agrees to divest equity ownership position in ScinoPharm Taiwan

Watson Pharmaceuticals, Inc. today announced that it signed an agreement on February 26, 2010 to divest its equity ownership position of approximately 31% of ScinoPharm Taiwan Ltd. The transaction is subject to the parties obtaining approvals from various government agencies in Taiwan, as well as other customary closing conditions.

2 Mar 2010

Physicians urge Senators to repeal Medicare cuts

The U.S. Senate's failure to act before today's 21 percent Medicare physician payment cut has put seniors at grave risk of reduced access to health care and choice of physician.

1 Mar 2010

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of the SUmiT Trial of its Urgent® PC Neuromodulation System that will be published in the April 2010 print edition of THE JOURNAL OF UROLOGY® and is now available on line.

1 Mar 2010

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.

1 Mar 2010

Kidney Cancer Canada: Survival, support, understanding, research and hope

Survival. Support. Understanding. Research. Hope. These are five words that mean a great deal to Kidney Cancer Canada as National Kidney Month kicks off this March.

27 Feb 2010

New Robotic Surgical Simulator created for robot-assisted surgery

A collaboration between the Center for Robotic Surgery at Roswell Park Cancer Institute and the University at Buffalo's School of Engineering and Applied Sciences has produced one of the world's first simulators that closely approximates the "touch and feel" of the da Vinci- robotic surgical system.

26 Feb 2010

Urology News and Research

Latest Urology News and Research

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Macroplastique effective for stress urinary incontinence in women

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

Cystoscopy: Cost-effective method of detecting tumors

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

Allergan celebrates 20th anniversary of BOTOX in Canada

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

My Little Miracle Essay Contest: Winners to receive education fund prizes to support their children's future

Watson Pharmaceuticals agrees to divest equity ownership position in ScinoPharm Taiwan

Physicians urge Senators to repeal Medicare cuts

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Kidney Cancer Canada: Survival, support, understanding, research and hope

New Robotic Surgical Simulator created for robot-assisted surgery

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Urology News and Research

Latest Urology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in